171 related articles for article (PubMed ID: 17512900)
1. The mechanism of action of nitric oxide-donating aspirin.
Kashfi K; Rigas B
Biochem Biophys Res Commun; 2007 Jul; 358(4):1096-101. PubMed ID: 17512900
[TBL] [Abstract][Full Text] [Related]
2. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
Kashfi K; Borgo S; Williams JL; Chen J; Gao J; Glekas A; Benedini F; Del Soldato P; Rigas B
J Pharmacol Exp Ther; 2005 Mar; 312(3):978-88. PubMed ID: 15528453
[TBL] [Abstract][Full Text] [Related]
3. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Konturek PC; Kania J; Burnat G; Hahn EG
J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
[TBL] [Abstract][Full Text] [Related]
4. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression.
Nath N; Labaze G; Rigas B; Kashfi K
Biochem Biophys Res Commun; 2005 Jan; 326(1):93-9. PubMed ID: 15567157
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets of nitric-oxide-donating aspirin in cancer.
Kashfi K; Rigas B
Biochem Soc Trans; 2005 Aug; 33(Pt 4):701-4. PubMed ID: 16042578
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention.
Williams JL; Nath N; Chen J; Hundley TR; Gao J; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2003 Nov; 63(22):7613-8. PubMed ID: 14633677
[TBL] [Abstract][Full Text] [Related]
7. NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation.
Chattopadhyay M; Goswami S; Rodes DB; Kodela R; Velazquez CA; Boring D; Crowell JA; Kashfi K
Cancer Lett; 2010 Dec; 298(2):204-11. PubMed ID: 20674154
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress.
Gao J; Liu X; Rigas B
Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17207-12. PubMed ID: 16282376
[TBL] [Abstract][Full Text] [Related]
9. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?
Yeh RK; Chen J; Williams JL; Baluch M; Hundley TR; Rosenbaum RE; Kalala S; Traganos F; Benardini F; del Soldato P; Kashfi K; Rigas B
Biochem Pharmacol; 2004 Jun; 67(12):2197-205. PubMed ID: 15163551
[TBL] [Abstract][Full Text] [Related]
10. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism.
Gao J; Kashfi K; Rigas B
J Pharmacol Exp Ther; 2005 Mar; 312(3):989-97. PubMed ID: 15528452
[TBL] [Abstract][Full Text] [Related]
11. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis.
Ouyang N; Williams JL; Rigas B
Carcinogenesis; 2006 Feb; 27(2):232-9. PubMed ID: 16141240
[TBL] [Abstract][Full Text] [Related]
12. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin.
Hulsman N; Medema JP; Bos C; Jongejan A; Leurs R; Smit MJ; de Esch IJ; Richel D; Wijtmans M
J Med Chem; 2007 May; 50(10):2424-31. PubMed ID: 17441704
[TBL] [Abstract][Full Text] [Related]
13. Novel agents for cancer prevention based on nitric oxide.
Rigas B
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1364-8. PubMed ID: 17956352
[TBL] [Abstract][Full Text] [Related]
14. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
Chattopadhyay M; Kodela R; Nath N; Dastagirzada YM; Velázquez-Martínez CA; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):715-22. PubMed ID: 22222427
[TBL] [Abstract][Full Text] [Related]
15. The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin.
Hua A; Mackenzie GG; Rigas B
Int J Oncol; 2009 Oct; 35(4):837-44. PubMed ID: 19724920
[TBL] [Abstract][Full Text] [Related]
16. Development of novel agents based on nitric oxide for the control of colon cancer.
Kozoni V; Rosenberg T; Rigas B
Acta Pharmacol Sin; 2007 Sep; 28(9):1429-33. PubMed ID: 17723176
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model.
Ouyang N; Williams JL; Tsioulias GJ; Gao J; Iatropoulos MJ; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2006 Apr; 66(8):4503-11. PubMed ID: 16618778
[TBL] [Abstract][Full Text] [Related]
18. Nitric-oxide-donating NSAIDs as agents for cancer prevention.
Rigas B; Kashfi K
Trends Mol Med; 2004 Jul; 10(7):324-30. PubMed ID: 15242680
[TBL] [Abstract][Full Text] [Related]
19. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
20. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells.
Spiegel A; Hundley TR; Chen J; Gao J; Ouyang N; Liu X; Go MF; Tsioulias GJ; Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):993-1000. PubMed ID: 16105666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
